
As a proven business leader with 6 years of experience heading a specialty business unit in the pharmaceutical industry, I have consistently delivered exceptional growth, market leadership, and successful product launches across high-value therapeutic areas including Hematology, Rheumatology, Dermatology, Ophthalmology, Oncology, Urology, and Gastroenterology. Managing a USD 12M portfolio and leading a high-performing team of 25, I have driven strategic initiatives that strengthened our market position, expanded our product footprint, and maximized revenue across both direct and partner channels.
KEY ACHIEVEMENTS
Biosimilar Leadership – Spearheaded growth in biosimilar portfolio (Rituximab, Etanercept, Adalimumab) with sustained double- and triple-digit growth:
• 2019–2020: +2,569% | 2020–2021: +204% | 2021–2022: +52% | 2022–2023: +30% | 2023–2024: +22%.
• As of Mar 2025: Rank #1 with 41% market share, +27.6% growth vs. market’s +47.6%, ROS 51%.
Oncology Expansion – Strengthened oncology business with consistent growth, culminating in a 40% surge in 2023–2024 and market leadership in Fulvestrant (MKS 67%, +46% growth; ROS 55%).
High-Impact Launches – Successfully launched and scaled multiple key brands, achieving rapid market penetration:
• Rixathon (2019) – #3 at launch, now Rank #2 MKS.
• Erelzi (2020) – #2 MKS.
• Hyrimoz (2021) – Achieved #1 MKS with strong YoY growth.
• Fulvestrant (2021) – MKS 67% with sustained growth.
• Abiraterone (2024) – MKS 21%.
• Sorafenib (2025) – Launched in early 2025.
CORE COMPETENCIES
Team Leadership • P&L Management • Market Access Strategy • Product Launch Excellence • Cross-functional Collaboration • Revenue Growth Optimization